22:45 , Sep 6, 2018 |  BC Extra  |  Company News

Management tracks: Rheos, Aileron

Immunometabolism company Rheos Medicines Inc. (Cambridge, Mass.) hired Sanjay Keswani as CEO. He was SVP and global head of neuroscience, ophthalmology and rare disease for the Pharma Research and Early Development (pRED) group at Roche...
22:32 , Aug 16, 2018 |  BC Extra  |  Company News

Management tracks: Achillion, Navidea

Rare disease company Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) hired Anthony Gibney as EVP and CBO. He was managing director and co-head of the biotechnology investment banking team at Leerink Partners. Immunotherapy company Navidea Biopharmaceuticals Inc. (NYSE-A:NAVB;...
22:03 , Sep 18, 2017 |  BC Extra  |  Company News

Management tracks: Kamada, Vertex, Addex, Achillion

Orphan disease company Kamada Ltd. (Tel Aviv:KMDA; NASDAQ:KMDA) said Deputy CEO and CFO Gil Efron will leave at the end of the year. Chaime Orlev will become CFO, effective Jan. 1, 2018. Orlev was CFO...
23:54 , Aug 7, 2017 |  BC Extra  |  Company News

Management tracks: Pfenex, Alvotech, uniQure

Biosimilars company Pfenex Inc. (NYSE-M:PFNX) named Evert Schimmelpennink CEO, president and secretary. He succeeds interim CEO Patrick Lucy, who will continue as CBO. Rasmus Rojkjaer was named CEO at biosimilar company Alvotech ehf (Reykjavik, Iceland),...
00:55 , Jan 21, 2017 |  BioCentury  |  Finance

Proving partners

Signet Healthcare Partners’ latest fund will test whether its new team can successfully implement the firm’s established investment strategy. Signet Healthcare Partners IV L.P. closed on Jan. 12 at $137.2 million to invest in commercial...
07:00 , Aug 22, 2016 |  BC Week In Review  |  Clinical News

Px563L: Phase Ia data

A double-blind, placebo-controlled, U.S. Phase Ia trial in about 54 healthy volunteers showed that 2 doses of 10 or 80 ug intramuscular Px563L given 28 days apart led to a TNA NF50 value of >=0.56...
07:00 , Aug 15, 2016 |  BC Week In Review  |  Company News

Pfenex, Pfizer deal

Pfizer terminated a deal with Pfenex, returning to the biotech worldwide rights to PF582 , a biosimilar of ophthalmic drug Lucentis ranibizumab. In February 2015, Pfenex granted Hospira Inc. exclusive, worldwide rights to develop and...
07:00 , Aug 8, 2016 |  BC Extra  |  Clinical News

Pfenex regains rights to Lucentis biosimilar, reports data

Pfenex Inc. (NYSE-M:PFNX) regained worldwide rights to PF582 and said the biosimilar of Lucentis ranibizumab met the primary endpoint of demonstrating similar safety and tolerability to its reference product in a Phase I/II study to...
07:00 , Aug 24, 2015 |  BC Week In Review  |  Company News

Pfenex, U.S. Department of Health and Human Services infectious news

Pfenex said HHS’s Biomedical Advanced Research and Development Authority (BARDA) awarded the company a five-year contract with a total potential value of $143.5 million to develop Px563L , a recombinant protective antigen (rPA) anthrax vaccine...
01:01 , Aug 18, 2015 |  BC Extra  |  Company News

Pfenex lands BARDA contract for anthrax vaccine

Pfenex Inc. (NYSE-M:PFNX) said HHS's Biomedical Advanced Research and Development Authority awarded it a five-year contract with a total potential value of $143.5 million to develop Px563L , a recombinant protective antigen ( rPA )...